SELECTA BIOSCIENCES INC. news, videos and press releases
For more news please use our advanced search feature.
SELECTA BIOSCIENCES INC. - More news...
SELECTA BIOSCIENCES INC. - More news...
- Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split
- Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
- Cartesian Therapeutics to Participate in Upcoming Investor Conferences
- Cartesian Therapeutics Announces New Employment Inducement Grant
- Cartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland
- Cartesian Therapeutics Announces New Employment Inducement Grants
- Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity
- Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis
- Selecta Biosciences Announces Merger with Cartesian Therapeutics
- Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi
- Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics
- Selecta Biosciences Announces Presentation of Data from Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout During Late-Breaking Session at the EULAR 2023 European Congress of Rheumatology
- Selecta Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
- Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update
- Thinking about buying stock in Selecta Biosciences, On Holding AG, eMagin, Harmonic, or Canadian Solar?
- Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint
- Selecta Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Update
- Selecta Biosciences to Participate at the SVB Securities Global Biopharma Conference
- Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease
- Selecta Biosciences Announces Next Generation IgA Protease Clinical Candidate Selection for IgA Nephropathy Program
- Selecta Biosciences Announces Appointment of Blaine Davis as Chief Financial Officer
- Selecta Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
- Selecta Biosciences to Host Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results and Provide Business Update
- Selecta Biosciences Announces Three Presentations at the Upcoming 29th Annual European Society of Gene and Cell Therapy (ESGCT) Conference
- Selecta Biosciences Board Member, Timothy Springer, Ph.D., Wins Lasker Award for Seminal Discovery of Key Adhesion Molecules that Mediate Immune Cell Interactions
- Selecta Biosciences to Participate in Upcoming Investor Conferences
- Selecta Biosciences to Participate at the H.C. Wainwright 24th Annual Global Investment Conference
- Selecta Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
- Selecta Biosciences to Host Conference Call and Webcast to Discuss Second Quarter 2022 Financial Results and Provide Business Update